ClinicalTrials.gg
CompletedNCT07061808LSQUpdated Jul 11, 2025

The Reliability and Validity of the Turkish Version of the LSQ

An observational study in Lipedema and Women, sponsored by Gazi University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Gazi University · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
59
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 41 studies in Lipedema with a site in Turkey — 18 open to participants now, 19 under way, none of them phase 3. Lipedema · Turkey.

Enrollment
18th of 27
59 · median 76
Started
2022
with 2 others
Observational
27 of 41
9 open now
Registered
15th of 41
by date
Lead sponsor
4 of 41
Gazi University

Among the 41 studies in Lipedema with a site in Turkey, this one is the 18th largest by enrollment of the 27 observational ones that give a count, is one of 3 that started in 2022, is one of 27 observational ones, and was the 15th registered.

Lipedema

85 studies on the registry are indexed under Lipedema; 32 are open to participants now.

This study's enrollment of 59 is below the median of 90 across 42 observational studies indexed under Lipedema.

Browse Lipedema studies →

Open to participants now

18 of the 41 studies in Lipedema with a site in Turkey are open now, in 1 country. Each count lists the studies.

All 18 open studies →

Where they have run

Who these studies take

Of the 19 Lipedema studies recruiting now, 3 (16%) set no upper age limit and 16 (84%) stop at 75 or younger; 0 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →
Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Lipedema with a site in Turkey, or all of them as a file.
02

Study summary

Abstract Background/ Aim: The aim of this study was to investigate the reliability and validity of the Turkish version of the Lipedema Screening Questionnaire (T-LSQ). Method: The study involved 59 female volunteers diagnosed with lipedema by a cardiovascular surgeon. Key demographics such as age, onset age, lipedema types and stages, clinical features, and BMI were recorded. The Turkish adaptation of the LSQ was performed in accordance with the protocol of Beaton. Confirmatory factor analysis was performed for structural validity. For concurrent validity, T- LSQ, the Lower Extremity Functional Scale (LEFS), the Lymphedema Life Impact Scale (LLIS), and the Lymphoedema Functioning, Disability and Health Quastionnaire for Lower Extremity Lymphedema (Lymph-ICF-LL) were applied and the correlation between the scale responses was analyzed. Test-retest and internal consistency reliability were performed.

03

Conditions studied

  • Lipedema
  • Women

Browse trials for

Keywords

  • lipedema
  • validity
  • reliability
  • Turkish adaptation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Information provided about the study and informed consent was obtained from voluntary participants. Participants who came to University hospital physiotherapy department for treatment or control purposes with the diagnoses of lipoedema, lipolymphoedema were included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • had no communication cognitive and mental problem
  • participant in Turkish

Exclusion criteria

Exclusion Criteria:

  • Patients with diagnoses of renal and heart failure
  • individuals with history of lower extremity surgery
  • individuals with severe arterial venous disease involving the lower extremity
  • individuals with active cancer disease or
  • individuals with severe acute infective disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
59 participants (actual)
Patient registry
No

Groups and cohorts

  • women diagnosed with lipoedema

    women diagnosed with lipoedema

    Diagnostic Test: Lipedema Screening Questionnaire

Interventions

  • Diagnostic testLipedema Screening Questionnaire

    The Lipoedema screening questionnaire (LSQ) is a practical tool that can be applied quickly and easily and is used to identify patients with lipoedema during history taking and physical examination.

06

What researchers measure

Primary outcomes

  1. The Validity and Reliability of Turkish version of the Lipedema Screening Questionnaire

    The Validity and Reliability of Turkish version of the Lipedema Screening Questionnaire: For validity, T-LSQ, Lower Extremity Functional Scale (LEFS), Lymphedema Life Impact Scale (LLIS) and Lymphedema Function, Disability and Health Questionnaire for Lower Extremity Lymphedema (Lymph-ICF-LL) were applied and correlation analysis between scale responses will be done. The LSQ questionnaire, whose reliability we measured, was applied at the beginning of the study and again after 10 days.

    Time frame: at 10-day intervals.

07

Study locations

1 site
  • aDepartment of Physiotherapy and Rehabilitation, Health Science Faculty, Gazi University, Ankara, Turkey
    Ankara, 06000, Turkey (Türkiye)
08

References and documents

Publications

  • Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens MR. Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): reliability and validity. Phys Ther. 2011 Jun;91(6):944-57. doi: 10.2522/ptj.20100087. Epub 2011 Apr 14. PubMed 21493748 ↗
  • Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007 Jan;60(1):34-42. doi: 10.1016/j.jclinepi.2006.03.012. Epub 2006 Aug 24. PubMed 17161752 ↗
  • Herbst KL, Kahn LA, Iker E, Ehrlich C, Wright T, McHutchison L, Schwartz J, Sleigh M, Donahue PM, Lisson KH, Faris T, Miller J, Lontok E, Schwartz MS, Dean SM, Bartholomew JR, Armour P, Correa-Perez M, Pennings N, Wallace EL, Larson E. Standard of care for lipedema in the United States. Phlebology. 2021 Dec;36(10):779-796. doi: 10.1177/02683555211015887. Epub 2021 May 28. PubMed 34049453 ↗
  • Mishra, Manit. (2016). Confirmatory Factor Analysis (CFA) as an Analytical Technique to Assess Measurement Error in Survey Research: A Review. Paradigm. 20. 97-112. 10.1177/0971890716672933.
  • Zinbarg, R.E., Revelle, W., Yovel, I. et al. Cronbach's α, Revelle's β, and Mcdonald's ω H : their relations with each other and two alternative conceptualizations of reliability. Psychometrika 70, 123-133 (2005). https://doi.org/10.1007/s11336-003-0974-7
  • Feise RJ, Michael Menke J. Functional rating index: a new valid and reliable instrument to measure the magnitude of clinical change in spinal conditions. Spine (Phila Pa 1976). 2001 Jan 1;26(1):78-86; discussion 87. doi: 10.1097/00007632-200101010-00015. PubMed 11148650 ↗
  • Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91. doi: 10.1097/00007632-200012150-00014. No abstract available. PubMed 11124735 ↗
  • Citaker S, Kafa N, Hazar Kanik Z, Ugurlu M, Kafa B, Tuna Z. Translation, cross-cultural adaptation and validation of the Turkish version of the Lower Extremity Functional Scale on patients with knee injuries. Arch Orthop Trauma Surg. 2016 Mar;136(3):389-95. doi: 10.1007/s00402-015-2384-6. Epub 2016 Jan 4. PubMed 26728274 ↗
  • Degirmenci B, Tuzun S, Of NS, Oral A, Sindel D. Reliability and validity of Turkish version of Lymphedema Life Impact Scale. Turk J Phys Med Rehabil. 2019 May 3;65(2):147-153. doi: 10.5606/tftrd.2019.3041. eCollection 2019 Jun. PubMed 31453555 ↗
  • Kostanoglu A, Hosbay Z, Tarakci E. Lymphoedema functioning, disability and health questionnaire Turkish version: translation, cross-cultural adaptation and validation. J Phys Ther Sci. 2016 Jun;28(6):1728-32. doi: 10.1589/jpts.28.1728. Epub 2016 Jun 28. PubMed 27390404 ↗
  • Begum, M. R. (2019). Validity and Reliability of Visual Analogue Scale (Vas) for Pain Measurement.
  • Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PubMed 1593914 ↗
  • Weiss J, Daniel T. VALIDATION OF THE LYMPHEDEMA LIFE IMPACT SCALE (LLIS): A CONDITION-SPECIFIC MEASUREMENT TOOL FOR PERSONS WITH LYMPHEDEMA. Lymphology. 2015 Sep;48(3):128-38. PubMed 26939160 ↗
  • Devoogdt N, De Groef A, Hendrickx A, Damstra R, Christiaansen A, Geraerts I, Vervloesem N, Vergote I, Van Kampen M. Lymphoedema Functioning, Disability and Health Questionnaire for Lower Limb Lymphoedema (Lymph-ICF-LL): reliability and validity. Phys Ther. 2014 May;94(5):705-21. doi: 10.2522/ptj.20130285. Epub 2014 Jan 10. PubMed 24415775 ↗
  • Binkley JM, Stratford PW, Lott SA, Riddle DL. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. Phys Ther. 1999 Apr;79(4):371-83. PubMed 10201543 ↗
  • Kerola T, Hiltunen M, Kettunen R, Hartikainen S, Sulkava R, Vuolteenaho O, Nieminen T. Mini-Mental State Examination score and B-type natriuretic peptide as predictors of cardiovascular and total mortality in an elderly general population. Ann Med. 2011 Dec;43(8):650-9. doi: 10.3109/07853890.2010.526137. Epub 2010 Oct 21. PubMed 20961273 ↗
  • Meier-Vollrath I, Schmeller W. [Lipoedema--current status, new perspectives]. J Dtsch Dermatol Ges. 2004 Mar;2(3):181-6. doi: 10.1046/j.1439-0353.2004.04051.x. German. PubMed 16281634 ↗
  • Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015 May;50(3):117-128. doi: 10.1097/NT.0000000000000092. Epub 2015 Apr 7. PubMed 27340299 ↗
  • Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin. 2012 Feb;33(2):155-72. doi: 10.1038/aps.2011.153. PubMed 22301856 ↗
  • WOLD LE, HINES EA Jr, ALLEN EV. Lipedema of the legs; a syndrome characterized by fat legs and edema. Ann Intern Med. 1951 May;34(5):1243-50. doi: 10.7326/0003-4819-34-5-1243. No abstract available. PubMed 14830102 ↗
  • Czerwinska M, Teodorczyk J, Hansdorfer-Korzon R. A Scoping Review of Available Tools in Measurement of the Effectiveness of Conservative Treatment in Lipoedema. Int J Environ Res Public Health. 2022 Jun 10;19(12):7124. doi: 10.3390/ijerph19127124. PubMed 35742373 ↗
  • Kruppa P, Georgiou I, Biermann N, Prantl L, Klein-Weigel P, Ghods M. Lipedema-Pathogenesis, Diagnosis, and Treatment Options. Dtsch Arztebl Int. 2020 Jun 1;117(22-23):396-403. doi: 10.3238/arztebl.2020.0396. PubMed 32762835 ↗
  • Szolnoky G, Nagy N, Kovacs RK, Dosa-Racz E, Szabo A, Barsony K, Balogh M, Kemeny L. Complex decongestive physiotherapy decreases capillary fragility in lipedema. Lymphology. 2008 Dec;41(4):161-6. PubMed 19306662 ↗
  • Buck DW 2nd, Herbst KL. Lipedema: A Relatively Common Disease with Extremely Common Misconceptions. Plast Reconstr Surg Glob Open. 2016 Sep 28;4(9):e1043. doi: 10.1097/GOX.0000000000001043. eCollection 2016 Sep. PubMed 27757353 ↗
  • Reich-Schupke S, Schmeller W, Brauer WJ, Cornely ME, Faerber G, Ludwig M, Lulay G, Miller A, Rapprich S, Richter DF, Schacht V, Schrader K, Stucker M, Ure C. S1 guidelines: Lipedema. J Dtsch Dermatol Ges. 2017 Jul;15(7):758-767. doi: 10.1111/ddg.13036. PubMed 28677175 ↗
  • Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation. Int J Mol Sci. 2021 Oct 29;22(21):11720. doi: 10.3390/ijms222111720. PubMed 34769153 ↗
  • Amato ACM, Amato FCM, Benitti DA, Amato LGL. Development of a questionnaire and screening model for lipedema. J Vasc Bras. 2020 Dec 11;19:e20200114. doi: 10.1590/1677-5449.200114. PubMed 34211528 ↗
  • Shavit E, Wollina U, Alavi A. Lipoedema is not lymphoedema: A review of current literature. Int Wound J. 2018 Dec;15(6):921-928. doi: 10.1111/iwj.12949. Epub 2018 Jun 29. PubMed 29956468 ↗
  • Child AH, Gordon KD, Sharpe P, Brice G, Ostergaard P, Jeffery S, Mortimer PS. Lipedema: an inherited condition. Am J Med Genet A. 2010 Apr;152A(4):970-6. doi: 10.1002/ajmg.a.33313. PubMed 20358611 ↗

Individual participant data

Plan to share: No — I don't feel the need to.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jun 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2025
First posted
Jul 11, 2025
StartActual
Oct 20, 2022
Primary completionActual
Jun 20, 2023
CompletionActual
Oct 25, 2023
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07061808
Lead sponsor
Gazi University
Responsible party
Ilke Keser (Proffesor, Gazi University) — Principal investigator
First posted
Jul 11, 2025
Start date
Oct 20, 2022
Primary completion
Jun 20, 2023
Completion
Oct 25, 2023
Last update
Jul 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion